Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Common Equity (2016 - 2025)

Historic Common Equity for Perspective Therapeutics (CATX) over the last 15 years, with Q3 2025 value amounting to $242.2 million.

  • Perspective Therapeutics' Common Equity fell 2625.95% to $242.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $242.2 million, marking a year-over-year decrease of 2625.95%. This contributed to the annual value of $290.7 million for FY2024, which is 28663.46% up from last year.
  • Perspective Therapeutics' Common Equity amounted to $242.2 million in Q3 2025, which was down 2625.95% from $265.7 million recorded in Q2 2025.
  • Perspective Therapeutics' 5-year Common Equity high stood at $341.0 million for Q2 2024, and its period low was $54.6 million during Q4 2022.
  • Its 5-year average for Common Equity is $151.9 million, with a median of $98.8 million in 2023.
  • As far as peak fluctuations go, Perspective Therapeutics' Common Equity surged by 119065.75% in 2021, and later crashed by 2625.95% in 2025.
  • Over the past 5 years, Perspective Therapeutics' Common Equity (Quarter) stood at $64.4 million in 2021, then fell by 15.14% to $54.6 million in 2022, then surged by 37.58% to $75.2 million in 2023, then surged by 286.63% to $290.7 million in 2024, then dropped by 16.67% to $242.2 million in 2025.
  • Its Common Equity stands at $242.2 million for Q3 2025, versus $265.7 million for Q2 2025 and $284.6 million for Q1 2025.